Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Precision BioSciences, Inc./ 8-K

Current Report · Items 2.02, 9.01 · 8-K

Precision BioSciences, Inc.

DTILNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Filed Aug 7, 2025Accepted Aug 7, 2025, 7:30 AM EDTCIK 1357874Accession 0001628280-25-038592
View company →Permanent SEC source ↗
Share

Company context

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of

Current securities

DTILNASDAQ · EQUITY · Current

Recent company filings

  1. Regulation FD Disclosure · Other EventsAug 24, 2026
  2. S-8 filingAug 7, 2026
  3. 10-Q filingAug 6, 2026
  4. Results of Operations and Financial ConditionAug 6, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureJul 27, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) dtil-20250807xex991.htm

EX-99.1 2 dtil-20250807xex991.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B; Announced safety and efficacy for Cohort 1 and safety data for Cohort 2 PBGENE-HBV demonstrated substantial antiviral activity in all Cohort 1 patients, with best responses achieving a 47-69% reduction in Hepatitis B surface antigen (HBsAg) and durable HBsAg reduction in one patient 7 months after initial dose administration Accelerated development of PBGENE-DMD as a potential first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD) Granted FDA Rare Pediatric Disease Designation and Orphan Drug Designation for PBGENE-DMD for the treatment of DMD; Clinical data expected in 2026. Extended expected cash runway to the second half of 2027 providing more than two years of operating cash DURHAM, N.C., August 7, 2025 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for di…

Open exhibit ↗